Injectable BMP-2 gene-activated scaffold for the repair of cranial bone defect in mice
Open Access
- 12 August 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Stem Cells Translational Medicine
- Vol. 9 (12) , 1631-1642
Abstract
Tissue engineering using adult human mesenchymal stem cells (MSCs) seeded within biomaterial scaffolds has shown the potential to enhance bone healing. Recently, we have developed an injectable, biodegradable methacrylated gelatin‐based hydrogel, which was especially effective in producing scaffolds in situ and allowed the delivery of high viable stem cells and gene vehicles. The well‐demonstrated benefits of recombinant adeno‐associated viral (rAAV) vector, including long‐term gene transfer efficiency and relative safety, combination of gene and cell therapies has been developed in both basic and translational research to support future bone tissue regeneration clinical trials. In this study, we have critically assessed the applicability of single‐step visible light (VL) photocrosslinking fabrication of gelatin scaffold to deliver rAAV encoding human bone morphogenetic protein‐2 (BMP‐2 ) gene to address the need for sustained BMP‐2 presence localized within scaffolds for the repair of cranial bone defect in mouse model. In this method, rAAV‐BMP‐2 and human bone marrow‐derived MSCs (hBMSCs) were simultaneously included into gelatin scaffolds during scaffold formation by VL illumination. We demonstrated that the subsequent release of rAAV‐BMP‐2 constructs from the scaffold matrix, which resulted in efficient in situ expression of BMP‐2 gene by hBMSCs seeded within the scaffolds, and thus induced their osteogenic differentiation without the supplement of exogenous BMP‐2. The reparative capacity of this novel stem cell‐seeded and gene‐activated scaffolds was further confirmed in the cranial defect in the severe combined immunodeficiency mice, revealed by imaging, histology, and immunohistochemistry at 6 weeks after cranial defect treatment.Keywords
Funding Information
- Commonwealth of PA Department of Health (SAP4100062224, SAP4100050913, SAP4100065563, SAP4100061184)
- National Institutes of Health (5R01EB019430)
- U.S. Department of War (W81XWH-14-2-0003, W81XWH-10-1-0850)
- National Institutes of Health (5R01EB019430)
- U.S. Department of War (W81XWH‐14‐2‐0003, W81XWH‐10‐1‐0850)
This publication has 42 references indexed in Scilit:
- Fibrin hydrogels for lentiviral gene delivery in vitro and in vivoJournal of Controlled Release, 2012
- In vitro evaluation of a double-stranded self-complementary adeno-associated virus type2 vector in bone marrow stromal cells for bone healingGenetic Vaccines and Therapy, 2011
- Bone Morphogenetic Protein Receptor in the Osteogenic Differentiation of Rat Bone Marrow Stromal CellsYonsei Medical Journal, 2010
- Photoinitiated polymerization of PEG-diacrylate with lithium phenyl-2,4,6-trimethylbenzoylphosphinate: polymerization rate and cytocompatibilityBiomaterials, 2009
- Development of Stepwise Osteogenesis-mimicking Matrices for the Regulation of Mesenchymal Stem Cell FunctionsJournal of Biological Chemistry, 2009
- Construction and analysis of compact muscle-specific promoters for AAV vectorsGene Therapy, 2008
- Matrices and scaffolds for delivery of bioactive molecules in bone and cartilage tissue engineeringAdvanced Drug Delivery Reviews, 2007
- Osteogenic Differentiation of Recombinant Adeno-Associated Virus 2-Transduced Murine Mesenchymal Stem Cells and Development of an Immunocompetent Mouse Model for Ex Vivo Osteoporosis Gene TherapyHuman Gene Therapy, 2004
- Gene therapy for new bone formation using adeno-associated viral bone morphogenetic protein-2 vectorsGene Therapy, 2003
- Synergistic enhancement of bone formation and healing by stem cell–expressed VEGF and bone morphogenetic protein-4Journal of Clinical Investigation, 2002